The most active researchers, institutions, and subtopics in Prostate Cancer, from recent PubMed records. Public authorship only, every figure verifiable by PMID.
Analyzed 271 recent PubMed papers (2021-2026) matching "prostate cancer androgen receptor PARP". Source: NLM PubMed. Generated July 2026.
| # | Researcher | Affiliation | Papers |
|---|---|---|---|
| 1 | Agarwal Neeraj | University of Utah | 16 |
| 2 | Fizazi Karim | University of Paris-Saclay | 12 |
| 3 | Sartor Oliver | Mayo Clinic | 10 |
| 4 | Sharp Adam | The Institute of Cancer Research | 9 |
| 5 | Castro Elena | Hospital Universitario 12 de Octubre | 9 |
| 6 | Gillessen Silke | Switzerland; Università della Svizzera Italiana | 7 |
| 7 | Yuan Wei | The Institute of Cancer Research | 7 |
| 8 | Mateo Joaquin | Vall d'Hebron Barcelona Hospital Campus | 7 |
| 9 | Hussain Maha | Northwestern University | 7 |
| 10 | Tilki Derya | University Hospital Hamburg Eppendorf | 6 |
| 11 | von Amsberg Gunhild | Universitätsklinikum Hamburg-Eppendorf | 6 |
| 12 | Bogdan Denisa | The Institute of Cancer Research | 6 |
| 13 | Paschalis Alec | The Institute of Cancer Research | 6 |
| 14 | Hussain Arif | University of Maryland Greenebaum Comprehensive Cancer Cen | 6 |
| 15 | Herrmann Ken | University Hospital Essen | 6 |
| 16 | Abida Wassim | Genitourinary Oncology Service | 6 |
| 17 | Saad Fred | Centre Hospitalier de l'Université de Montréal | 6 |
| 18 | Carreira Suzanne | The Institute of Cancer Research | 5 |
Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate C (2026) · PMID 42457456
Evaluation of Efficacy and Safety of Olaparib in Combination With Abiraterone for the Treatment of Metastatic Castration-Resistant (2026) · PMID 42431109
[How to prevent and manage PARP inhibitor-related hematological toxicities in prostate cancer?]. (2026) · PMID 42425824
Advances in systemic therapies for advanced prostate cancer. (2026) · PMID 42419784
Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate c (2026) · PMID 42414479
A full Prostate Cancer brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.